Quinlan T. Mewborne

Quinlan T. Mewborne

Auto-generated profile, based on publicly available information

Quinlan T. Mewborne

Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JGJunli Gao
Junli Gao
QMQuinlan T. Mewborne
Quinlan T. Mewborne
AGAmandeep Girdhar
Amandeep Girdhar
USUdit Sheth
Udit Sheth
ACAlyssa N. Coyne
Alyssa N. Coyne
KZKe Zhang
Ke Zhang
Arginine-rich dipeptide repeat proteins (R-DPRs), abnormal translational products of a GGGGCC hexanucleotide repeat expansion in C9ORF72 , play a critical role in C9ORF72 -related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), the most common genetic form of the disorders (c9ALS/FTD). R-DPRs form liquid condensates in vitro, induce stress granule formation in cultured cells, aggregate, and sometimes coaggregate with TDP-43 in postmortem tissue from patients with c9ALS/FTD. However, how these processes are regulated is unclear. Here, we show that loss of poly(ADP-ribose) (PAR) suppresses neurodegeneration in c9ALS/FTD fly models and neurons differentiated from patient-derived induced pluripotent stem cells. Mechanistically, PAR induces R-DPR condensation and promotes R-DPR–induced stress granule formation and TDP-43 aggregation. Moreover, PAR associates with insoluble R-DPR and TDP-43 in postmortem tissue from patients. These findings identified PAR as a promoter of R-DPR toxicity and thus a potential target for treating c9ALS/FTD.